Bilimsel çalışmalar

Doç. Dr. Murad Gulıyev

68 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

    Medicina, 2026

    DOI 10.3390/medicina62050984 PMID 42195237 Açık erişimli tam metinKaynak: OpenAlex

  2. Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16868-5 Açık erişimli tam metinKaynak: OpenAlex

  3. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Açık erişimli tam metinKaynak: OpenAlex

  4. Clinicopathological Predictors of Axillary Pathological Complete Response and Its Prognostic Significance in Clinically Node-Positive (cN+), HER2-Positive Breast Cancer Following Neoadjuvant Therapy

    Medicina, 2026

    DOI 10.3390/medicina62010200 PMID 41597486 Açık erişimli tam metinKaynak: OpenAlex

  5. Comparative Prognostic Value of Systemic Inflammation-Based Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with First-Line Immunotherapy

    Biomedicines, 2026

    DOI 10.3390/biomedicines14081825 PMID 42652206 Açık erişimli tam metinKaynak: OpenAlex

  6. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2662201 PMID 42011533 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  7. Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

    Cancers, 2026

    DOI 10.3390/cancers18071170 PMID 41976392 Açık erişimli tam metinKaynak: OpenAlex

  8. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041657 PMID 41753346 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  9. Prognostic Impact of PET/CT-Derived Sarcopenia in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15103736 PMID 42194697 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  10. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

    Cancers, 2026

    DOI 10.3390/cancers18132127 PMID 42449669 Açık erişimli tam metinKaynak: OpenAlex

  11. Diagnostic utility and discriminative ability of cholesterol-modified prognostic nutritional index and inflammatory indicators in colorectal cancer: a retrospective case-control study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-43288-z PMID 41803323 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  12. An integrated host vulnerability score is associated with survival in advanced NSCLC treated with nivolumab: a PET/CT-based real-world study

    BMC Pulmonary Medicine, 2026

    DOI 10.1186/s12890-026-04496-5 PMID 42458381 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  13. Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

    Medicina, 2026

    DOI 10.3390/medicina62030488 PMID 41901569 Açık erişimli tam metinKaynak: OpenAlex

  14. Prognostic value of the pretreatment CA19-9/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort study

    Medicine, 2026

    DOI 10.1097/md.0000000000048191 PMID 41961685 Açık erişimli tam metinKaynak: OpenAlex

  15. Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study

    Breast Cancer Targets and Therapy, 2026

    DOI 10.2147/bctt.s598598 PMID 42011243 Açık erişimli tam metinKaynak: OpenAlex

  16. Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15083067 PMID 42074868 Açık erişimli tam metinKaynak: OpenAlex

  17. Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS)

    Journal of Oncology Pharmacy Practice, 2026

    DOI 10.1177/10781552261447836 PMID 42089770 Kaynak: OpenAlex

  18. 543eP Can baseline immune inflammation predict outcomes? The role of the pan-immune inflammation value in HR-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.107565 Kaynak: OpenAlex

  19. Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer

    Figshare, 2026

    DOI 10.6084/m9.figshare.32605592 Kaynak: OpenAlex

  20. Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer

    Current Medical Research and Opinion, 2026

    DOI 10.1080/03007995.2026.2682050 PMID 42258330 Kaynak: OpenAlex

  21. Long-term outcomes of rare pure histological subtypes of breast cancer in a tertiary single-center retrospective cohort

    Discover Oncology, 2026

    DOI 10.1007/s12672-026-05211-w PMID 42265489 Açık erişimli tam metinKaynak: OpenAlex

  22. Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-58205-7 PMID 42304044 Açık erişimli tam metinKaynak: OpenAlex

  23. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33060365 PMID 42346265 Açık erişimli tam metinKaynak: OpenAlex

  24. Baseline Serum Albumin-to-Creatinine Ratio as an Independent Prognostic Marker in De Novo Metastatic HER2-negative Gastric Cancer

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-3-3 Kaynak: OpenAlex

  25. Does the CRP/Albumin Ratio Independently Predict Survival in Metastatic Colorectal Cancer? Insights from a Propensity Score-Matched Cohort

    Cancers, 2026

    DOI 10.3390/cancers18152425 PMID 42588644 Açık erişimli tam metinKaynak: OpenAlex

  26. Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16664-1 Açık erişimli tam metinKaynak: OpenAlex

  27. Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort

    Medicina, 2026

    DOI 10.3390/medicina62081601 PMID 42654498 Açık erişimli tam metinKaynak: OpenAlex

  28. Additional file 1 of An integrated host vulnerability score is associated with survival in advanced NSCLC treated with nivolumab: a PET/CT-based real-world study

    Figshare, 2026

    DOI 10.6084/m9.figshare.33433251 Kaynak: OpenAlex

  29. Prognostic Value of Baseline Endothelial Activation and Stress Index in Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors

    Cerrahpasa Medical Journal, 2026

    DOI 10.5152/cjm.2026.26053 Kaynak: OpenAlex

  30. Landmark-based stratification by at least 90% prostate-specific antigen decline and prostate-specific antigen nadir in androgen receptor pathway inhibitor–treated metastatic hormone-sensitive prostate cancer

    Prostate International, 2026

    DOI 10.1016/j.prnil.2026.09.005 Kaynak: OpenAlex

  31. Pretreatment CALLY Index and Survival Outcomes in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab: A Multicenter Retrospective Study

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.269359 Kaynak: OpenAlex

  32. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 atıf (Europe PMC) Kaynak: OpenAlex

  33. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

    Future Oncology, 2025

    DOI 10.1080/14796694.2025.2570637 PMID 41103123 Açık erişimli tam metinKaynak: OpenAlex

  34. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61030490 PMID 40142301 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  35. First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14134568 PMID 40648939 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  36. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-87553-z PMID 39863702 Açık erişimli tam metinKaynak: OpenAlex

  37. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors

    Cancers, 2025

    DOI 10.3390/cancers17040693 PMID 40002286 14 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  38. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14041071 PMID 40004601 9 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  39. Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-91102-z PMID 39984593 11 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  40. The impact of low HER2 expression on clinicopathological features and clinical outcomes in patients with metastatic gastric cancer

    Clinics and Research in Hepatology and Gastroenterology, 2025

    DOI 10.1016/j.clinre.2025.102646 PMID 40617321 5 atıf (Europe PMC) Kaynak: OpenAlex

  41. Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease

    International Journal of Hematology, 2025

    DOI 10.1007/s12185-025-03958-6 PMID 40032738 5 atıf (Europe PMC) Kaynak: OpenAlex

  42. Prognostic Significance of Inflammatory and Nutritional Biomarkers in Patients with Metastatic Gastric Cancer

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2024.106668 Kaynak: OpenAlex

  43. Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer

    Medicina, 2025

    DOI 10.3390/medicina61091508 PMID 41010899 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  44. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

    癌症：英文版, 2025

    DOI 10.1002/cac2.70003 PMID 39927571 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  45. Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14186469 PMID 41010673 Açık erişimli tam metinKaynak: OpenAlex

  46. Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70165 PMID 40968962 1 atıf (Europe PMC) Kaynak: OpenAlex

  47. Evaluating the Prognostic Role of Pan-Immune-Inflammation Value in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25038 Kaynak: OpenAlex

  48. The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf186 PMID 40577354 Açık erişimli tam metinKaynak: OpenAlex

  49. Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

    Immunotherapy, 2025

    DOI 10.1080/1750743x.2025.2527019 PMID 40611593 Açık erişimli tam metinKaynak: OpenAlex

  50. 197P Immune-mediated upper gastrointestinal system toxicities in patients receiving immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS)

    Immuno-Oncology Technology, 2025

    DOI 10.1016/j.iotech.2025.101280 Kaynak: OpenAlex